Phase II evaluation of AMSA in patients with stage III--IV malignant melanoma.
D000328:Adult; D000368:Aged; D000585:Aminacrine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D000609:Aminoacridines / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged
D000609:Aminoacridines; D000970:Antineoplastic Agents; D000585:Aminacrine; C013389:4'-(9-acridinylamino)methanesulfonanilide